The erythropoietin‐derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia

20224 citationsJournal Articlegold Open Access

Authors

Sandra Palus · Berlin Institute of Health at Charité - Universitätsmedizin Berlin

Yulia Elkina · Berlin Institute of Health at Charité - Universitätsmedizin Berlin

Tanja Braun · Berlin Institute of Health at Charité - Universitätsmedizin Berlin

Stephan von Haehling · Universitätsmedizin Göttingen

Wolfram Döhner · Berlin Institute of Health at Charité - Universitätsmedizin Berlin

Stefan D. Anker · Berlin Institute of Health at Charité - Universitätsmedizin Berlin

Abstract

Taken together these results suggest that ARA 284 can be considered beneficial in experimental CC and it remains to be seen, if it can have similar beneficial effects in CC patient.

Topics & Keywords

Erythropoietin and Anemia Treatment Vitamin D Research Studies PARP inhibition in cancer therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Cachexia Sarcopenia and Muscle

Volume 13, Issue 4, pp. 2202-2210

DOI: 10.1002/jcsm.13009

Field-Weighted Citation Impact: 0.64